Episodes (Page 4)
✨
The Yescarta CAR-T therapy launch faced both successes and challenges.
Harris Kaplan
✨
Pfizer outlines its strategic direction in oncology development.
✨
Pfizer detailed its future plans for oncology drug development.
✨
Tahir Amin of I-MAK discusses how patent monopolies hinder drug competition.
Tahir Amin
✨
Shez Partovi discusses Philips' strategy for increasing AI adoption in healthcare.
✨
Lilly explores Zepbound for autoimmune diseases, expanding its therapeutic reach.
✨
Lilly explores Zepbound for autoimmune diseases, expanding its therapeutic reach.
✨
Deloitte's Liz Hampson explains the socioeconomic case for preventative healthcare.
Elizabeth Hampson
✨
The Pentagon designated WuXi Apptec a 'Chinese military company,' raising supply chain concerns.
Maaisha Osman
Nielsen Hobbs
Sue Sutter
✨
US drug shortages are easing, but product discontinuations are increasing.
✨
Flagship Pioneering discusses expansion into the Korean biotech ecosystem.
Andre Andonian
Byung-kun Lee
✨
Revolution's daraxonrasib shows promise at ASCO.
✨
Revolution's daraxonrasib shows promise at ASCO; Merck outlines oncology vision.
✨
Exploring GLP-1s potential in cancer treatment and Novartis' cardiovascular strategy.
✨
Supreme Court upholds generic 'skinny labels,' impacting industry adaptation.
David Wallace
Derrick Gingery
Maaisha Osman
Nielsen Hobbs
Sue Sutter
✨
Episode: Ambu CEO Britt Meelby Jensen on EU competitivity and compromise
Britt Meelby Jensen
✨
GLP-1 agonists' potential role in cancer therapy is examined.
✨
Soley Therapeutics CEO discusses decoding cell stress for oncology pipeline.
David Wild
Yerem Yeghiazarians
✨
Potential mandatory NDAs for FDA staff could impact agency activities.
Derrick Gingery
Nielsen Hobbs
Sue Sutter
✨
Industry grapples with Most Favored Nation (MFN) policy fallout.